Boosting cancer treatment effects using ATM targeting
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy
This study is looking at how focusing on a protein called ATM can make cancer treatments like radiation and immunotherapy work better by boosting the immune system's ability to fight tumors, which could lead to improved results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11026438 on NIH RePORTER |
What this research studies
This research investigates how targeting a specific protein called ATM can enhance the effectiveness of radiotherapy and immunotherapy in cancer treatment. By manipulating the tumor environment, the goal is to increase the presence of immune cells that fight cancer, making the tumors more responsive to therapies. The study will explore the mechanisms behind this approach and test its effectiveness in improving patient outcomes. Patients may benefit from a more effective treatment strategy that combines these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that have a high mutational burden or inflammatory characteristics, who are currently undergoing or considering immunotherapy or radiotherapy.
Not a fit: Patients with tumors that do not exhibit high mutational burden or inflammatory phenotypes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment options that are more effective for a larger number of patients.
How similar studies have performed: Previous research has shown promising results in enhancing cancer treatment through similar approaches, indicating potential for success in this study.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Zhang, Jennifer Yunyan — Duke University
- Study coordinator: Zhang, Jennifer Yunyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.